Immune-related adverse events of immune checkpoint inhibitors: a review

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Qinan, Wu, Liuyun, Han, Lizhu, Zheng, Xingyue, Tong, Rongsheng, Li, Lian, Bai, Lan, Bian, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247998/
https://www.ncbi.nlm.nih.gov/pubmed/37304306
http://dx.doi.org/10.3389/fimmu.2023.1167975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247998/
https://www.ncbi.nlm.nih.gov/pubmed/37304306
http://dx.doi.org/10.3389/fimmu.2023.1167975

Ejemplares similares